{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:48:19Z","timestamp":1789501699200,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["EPIPROPER"],"award-info":[{"award-number":["EPIPROPER"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["2024-1.2.2-ERA_NET-2024-00015"],"award-info":[{"award-number":["2024-1.2.2-ERA_NET-2024-00015"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-025-01963-5","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:22:39Z","timestamp":1763180559000},"page":"3335-3350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting the HMGB1-IL32 pathway to alleviate T cell exhaustion in epithelial ovarian cancer"],"prefix":"10.1007","volume":"48","author":[{"given":"Ankita","family":"Murmu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5772-3766","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"1963_CR1","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA, Elsevier. Ovarian cancer. Lancet. 2014;384:1376\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(13)62146-7.","journal-title":"Lancet"},{"key":"1963_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY, et al. Ovarian cancer. Nat Rev Dis Primers. 2016;2:1\u201322. https:\/\/doi.org\/10.1038\/nrdp.2016.61.","journal-title":"Nat Rev Dis Primers"},{"key":"1963_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, et al. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022;151:1535\u201341. https:\/\/doi.org\/10.1002\/ijc.34002.","journal-title":"Int J Cancer"},{"key":"1963_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ygyno.2019.12.047","volume":"157","author":"CJ Cabasag","year":"2020","unstructured":"Cabasag CJ, Butler J, Arnold M, Rutherford M, Bardot A, Ferlay J, et al. Exploring variations in ovarian cancer survival by age and stage (ICBP survmark-2): a population-based study. Gynecol Oncol. 2020;157:234\u201344. https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.047.","journal-title":"Gynecol Oncol"},{"key":"1963_CR5","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonz\u00e1lez-Mart\u00edn A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31:1148\u201359. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.004.","journal-title":"Ann Oncol"},{"key":"1963_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9:210\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0715.","journal-title":"Cancer Discov"},{"key":"1963_CR7","doi-asserted-by":"publisher","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","volume":"28","author":"K Odunsi","year":"2017","unstructured":"Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28:viii1-7. https:\/\/doi.org\/10.1093\/annonc\/mdx444.","journal-title":"Ann Oncol"},{"key":"1963_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","volume":"16","author":"PP Santoiemma","year":"2015","unstructured":"Santoiemma PP, Powell DJ. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16:807\u201320. https:\/\/doi.org\/10.1080\/15384047.2015.1040960.","journal-title":"Cancer Biol Ther"},{"key":"1963_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933\u201359. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1808.","journal-title":"Cancer Discov"},{"key":"1963_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"Ovarian Tumor Tissue Analysis (OTTA) Consortium","year":"2017","unstructured":"Ovarian Tumor Tissue Analysis (OTTA) Consortium. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3:e173290. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3290.","journal-title":"JAMA Oncol"},{"key":"1963_CR11","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1158\/1078-0432.CCR-20-4394","volume":"27","author":"CM Laumont","year":"2021","unstructured":"Laumont CM, Wouters MCA, Smazynski J, Gierc NS, Chavez EA, Chong LC, et al. Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer. Clin Cancer Res. 2021;27:4089\u2013100. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4394.","journal-title":"Clin Cancer Res"},{"key":"1963_CR12","doi-asserted-by":"publisher","unstructured":"Yu Y-R, Imrichova H, Wang H, Chao T, Xiao Z, Gao M, et al. Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nat Immunol. 2020;21:1540\u201351. https:\/\/doi.org\/10.1038\/s41590-020-0793-3.","DOI":"10.1038\/s41590-020-0793-3"},{"key":"1963_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-020-00292-x","volume":"22","author":"E Armingol","year":"2021","unstructured":"Armingol E, Officer A, Harismendy O, Lewis NE, Nature Publishing Group. Deciphering cell\u2013cell interactions and communication from gene expression. Nat Rev Genet. 2021;22:71\u201388. https:\/\/doi.org\/10.1038\/s41576-020-00292-x.","journal-title":"Nat Rev Genet"},{"key":"1963_CR14","doi-asserted-by":"publisher","unstructured":"Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11:2285. https:\/\/doi.org\/10.1038\/s41467-020-16164-1.","DOI":"10.1038\/s41467-020-16164-1"},{"key":"1963_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","volume":"39","author":"M Hornburg","year":"2021","unstructured":"Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 2021;39:928-944.e6. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.004.","journal-title":"Cancer Cell"},{"key":"1963_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-024-05826-1","volume":"7","author":"C Chai","year":"2024","unstructured":"Chai C, Liang L, Mikkelsen NS, Wang W, Zhao W, Sun C, et al. Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer. Commun Biol. 2024;7:1\u201315. https:\/\/doi.org\/10.1038\/s42003-024-05826-1.","journal-title":"Commun Biol"},{"key":"1963_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-023-05733-x","volume":"7","author":"L Zhang","year":"2024","unstructured":"Zhang L, Cascio S, Mellors JW, Buckanovich RJ, Osmanbeyoglu HU. Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer. Commun Biol. 2024;7:1\u201314. https:\/\/doi.org\/10.1038\/s42003-023-05733-x.","journal-title":"Commun Biol"},{"key":"1963_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija R, Farrell JA, Gennert D, Schier AF, Regev A, Nature Publishing Group. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33:495\u2013502. https:\/\/doi.org\/10.1038\/nbt.3192.","journal-title":"Nat Biotechnol"},{"key":"1963_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta M, Corria-Osorio J, M\u00fcller S, Cubas R, Coukos G, Carmona SJ, et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat Commun. 2021;12:2965. https:\/\/doi.org\/10.1038\/s41467-021-23324-4.","journal-title":"Nat Commun"},{"key":"1963_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566:496\u2013502. https:\/\/doi.org\/10.1038\/s41586-019-0969-x.","journal-title":"Nature"},{"key":"1963_CR21","doi-asserted-by":"publisher","unstructured":"Jin S, Plikus MV, Nie Q. CellChat for systematic analysis of cell-cell communication from single-cell and spatially resolved transcriptomics [Internet]. bioRxiv; 2023 [cited 2024 May 29]. p. 2023.11.05.565674. https:\/\/doi.org\/10.1101\/2023.11.05.565674","DOI":"10.1101\/2023.11.05.565674"},{"key":"1963_CR22","doi-asserted-by":"publisher","unstructured":"Dimitrov D, T\u00fcrei D, Garrido-Rodriguez M, Burmedi PL, Nagai JS, Boys C, et al. Comparison of methods and resources for cell-cell communication inference from single-cell RNA-seq data. Nat Commun. 2022;13:3224. https:\/\/doi.org\/10.1038\/s41467-022-30755-0.","DOI":"10.1038\/s41467-022-30755-0"},{"key":"1963_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18873-z","volume":"11","author":"R Hou","year":"2020","unstructured":"Hou R, Denisenko E, Ong HT, Ramilowski JA, Forrest ARR. Predicting cell-to-cell communication networks using NATMI. Nat Commun. 2020;11:5011. https:\/\/doi.org\/10.1038\/s41467-020-18873-z.","journal-title":"Nat Commun"},{"key":"1963_CR24","doi-asserted-by":"publisher","unstructured":"Raredon MSB, Yang J, Garritano J, Wang M, Kushnir D, Schupp JC, et al. Computation and visualization of cell\u2013cell signaling topologies in single-cell systems data using connectome. Sci Rep. 2022;12:4187. https:\/\/doi.org\/10.1038\/s41598-022-07959-x.","DOI":"10.1038\/s41598-022-07959-x"},{"key":"1963_CR25","doi-asserted-by":"publisher","unstructured":"Wang Y, Wang R, Zhang S, Song S, Jiang C, Han G, et al. iTALK: an R package to characterize and illustrate intercellular communication [Internet]. bioRxiv; 2019 [cited 2024 Dec 2]. p. 507871. https:\/\/doi.org\/10.1101\/507871","DOI":"10.1101\/507871"},{"key":"1963_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa183","volume":"48","author":"S Cabello-Aguilar","year":"2020","unstructured":"Cabello-Aguilar S, Alame M, Kon-Sun-Tack F, Fau C, Lacroix M, Colinge J. SingleCellSignalR: inference of intercellular networks from single-cell transcriptomics. Nucleic Acids Res. 2020;48:e55. https:\/\/doi.org\/10.1093\/nar\/gkaa183.","journal-title":"Nucleic Acids Res"},{"key":"1963_CR27","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R, Nature Publishing Group. CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes. Nat Protoc. 2020;15:1484\u2013506. https:\/\/doi.org\/10.1038\/s41596-020-0292-x.","journal-title":"Nat Protoc"},{"key":"1963_CR28","doi-asserted-by":"publisher","unstructured":"Sang-aram C, Browaeys R, Seurinck R, Saeys Y. Unraveling cell-cell communication with NicheNet by inferring active ligands from transcriptomics data [Internet]. arXiv; 2024 [cited 2024 Nov 25]. https:\/\/doi.org\/10.48550\/arXiv.2404.16358","DOI":"10.48550\/arXiv.2404.16358"},{"key":"1963_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22:209\u201323. https:\/\/doi.org\/10.1038\/s41577-021-00574-3.","journal-title":"Nat Rev Immunol"},{"key":"1963_CR30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M, Nature Publishing Group. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"key":"1963_CR31","doi-asserted-by":"publisher","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326\u201336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6.","DOI":"10.1038\/s41590-019-0312-6"},{"key":"1963_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L, American Association for the Advancement of Science. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4-328rv4. https:\/\/doi.org\/10.1126\/scitranslmed.aad7118.","journal-title":"Sci Transl Med"},{"key":"1963_CR33","doi-asserted-by":"publisher","unstructured":"Wang W, Green M, Choi JE, Gij\u00f3n M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270\u20134. https:\/\/doi.org\/10.1038\/s41586-019-1170-y.","DOI":"10.1038\/s41586-019-1170-y"},{"key":"1963_CR34","doi-asserted-by":"publisher","unstructured":"Sun J, Yan C, Xu D, Zhang Z, Li K, Li X, et al. Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy. Br J Cancer. 2022;126:1570\u201380. https:\/\/doi.org\/10.1038\/s41416-021-01692-4.","DOI":"10.1038\/s41416-021-01692-4"},{"key":"1963_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","volume":"165","author":"W Wang","year":"2016","unstructured":"Wang W, Kryczek I, Dost\u00e1l L, Lin H, Tan L, Zhao L, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell. 2016;165:1092\u2013105. https:\/\/doi.org\/10.1016\/j.cell.2016.04.009.","journal-title":"Cell"},{"key":"1963_CR36","doi-asserted-by":"publisher","unstructured":"F\u00e4rkkil\u00e4 A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020;11:1459. https:\/\/doi.org\/10.1038\/s41467-020-15315-8.","DOI":"10.1038\/s41467-020-15315-8"},{"issue":"2","key":"1963_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","volume":"54","author":"R Chen","year":"2022","unstructured":"Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med. 2022;54(2):91\u2013102. https:\/\/doi.org\/10.1038\/s12276-022-00736-w.","journal-title":"Exp Mol Med"},{"key":"1963_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00950-x","volume":"13","author":"S Wang","year":"2020","unstructured":"Wang S, Zhang Y. HMGB1 in inflammation and cancer. J Hematol Oncol. 2020;13:116. https:\/\/doi.org\/10.1186\/s13045-020-00950-x.","journal-title":"J Hematol Oncol"},{"key":"1963_CR39","doi-asserted-by":"publisher","unstructured":"Hubert P, Roncarati P, Demoulin S, Pilard C, Ancion M, Reynders C, et al. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J Immunother Cancer. 2021;9:e001966. https:\/\/doi.org\/10.1136\/jitc-2020-001966.","DOI":"10.1136\/jitc-2020-001966"},{"key":"1963_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205081","volume":"15","author":"L Schr\u00f6der","year":"2023","unstructured":"Schr\u00f6der L, Rupp ABA, Gihr KME, Kobilay M, Domroese CM, Mallmann MR, et al. Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies. Cancers. 2023;15:5081. https:\/\/doi.org\/10.3390\/cancers15205081.","journal-title":"Cancers"},{"key":"1963_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-019-0247-4","volume":"14","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Yang S, Yang Y, Liu T. Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells. Infect Agent Cancer. 2019;14:27. https:\/\/doi.org\/10.1186\/s13027-019-0247-4.","journal-title":"Infect Agent Cancer"},{"key":"1963_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.02.025","volume":"174","author":"JT Hong","year":"2017","unstructured":"Hong JT, Son DJ, Lee CK, Yoon D-Y, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017;174:127\u201337. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.025.","journal-title":"Pharmacol Ther"},{"key":"1963_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR, Nature Publishing Group. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353. https:\/\/doi.org\/10.1038\/s41571-021-00588-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1963_CR44","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1158\/0008-5472.CAN-17-0740","volume":"77","author":"P Lamichhane","year":"2017","unstructured":"Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, et al. IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res. 2017;77:6667\u201378. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0740.","journal-title":"Cancer Res"},{"key":"1963_CR45","doi-asserted-by":"publisher","unstructured":"Liu Y, Zhou N, Zhou L, Wang J, Zhou Y, Zhang T, et al. IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Nat Immunol. 2021;22:358\u201369. https:\/\/doi.org\/10.1038\/s41590-020-00850-9.","DOI":"10.1038\/s41590-020-00850-9"},{"key":"1963_CR46","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.canlet.2018.10.015","volume":"442","author":"S Wen","year":"2019","unstructured":"Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin \u03b23\u2013p38 MAPK signalling. Cancer Lett. 2019;442:320\u201332. https:\/\/doi.org\/10.1016\/j.canlet.2018.10.015.","journal-title":"Cancer Lett"},{"key":"1963_CR47","doi-asserted-by":"publisher","unstructured":"Chang Y-T, Prompsy P, Kimeswenger S, Tsai Y-C, Ignatova D, Pavlova O, et al. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides. Nat Commun. 2024;15:752. https:\/\/doi.org\/10.1038\/s41467-024-45083-8.","DOI":"10.1038\/s41467-024-45083-8"},{"key":"1963_CR48","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ, Nature Publishing Group. P53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471\u201380. https:\/\/doi.org\/10.1038\/s41568-020-0262-1.","journal-title":"Nat Rev Cancer"},{"key":"1963_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduct Target Ther. 2023;8:1\u201335. https:\/\/doi.org\/10.1038\/s41392-023-01347-1.","journal-title":"Signal Transduct Target Ther"},{"key":"1963_CR50","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","volume":"39","author":"M Ghosh","year":"2021","unstructured":"Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494-508.e5. https:\/\/doi.org\/10.1016\/j.ccell.2021.01.003.","journal-title":"Cancer Cell"},{"key":"1963_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature Nature Publishing Group. 2011;474:609\u201315. https:\/\/doi.org\/10.1038\/nature10166.","journal-title":"Nature Nature Publishing Group"},{"key":"1963_CR52","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","volume":"23","author":"D Tang","year":"2023","unstructured":"Tang D, Kang R, Zeh HJ, Lotze MT, Nature Publishing Group. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol. 2023;23:824\u201341. https:\/\/doi.org\/10.1038\/s41577-023-00894-6.","journal-title":"Nat Rev Immunol"},{"key":"1963_CR53","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727\u201342.","journal-title":"Am J Cancer Res"},{"key":"1963_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05002-3","volume":"22","author":"Q Zhu","year":"2024","unstructured":"Zhu Q, Yang Y, Chen K, Zhang Q, Huang Y, Jian S. Diffuse large B-cell lymphoma: the significance of CD8+ tumor-infiltrating lymphocytes exhaustion mediated by TIM3\/Galectin-9 pathway. J Transl Med. 2024;22:174. https:\/\/doi.org\/10.1186\/s12967-024-05002-3.","journal-title":"J Transl Med"},{"key":"1963_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01455-z","volume":"22","author":"M Huang","year":"2024","unstructured":"Huang M, Yu X, Wang Q, Jiang Z, Li X, Chen W, et al. The immune checkpoint TIGIT\/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K\/AKT\/mTOR signaling. Cell Commun Signal. 2024;22:35. https:\/\/doi.org\/10.1186\/s12964-023-01455-z.","journal-title":"Cell Commun Signal"},{"key":"1963_CR56","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41388-024-03271-2","volume":"44","author":"S Li","year":"2025","unstructured":"Li S, Lin J, Huang L, Hu S, Wang M, Sun W, et al. STK31 drives tumor immune evasion through STAT3-IL-6 mediated CD8+ T cell exhaustion. Oncogene. 2025;44:1452\u201362. https:\/\/doi.org\/10.1038\/s41388-024-03271-2.","journal-title":"Oncogene"},{"key":"1963_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216494","volume":"581","author":"R Chen","year":"2024","unstructured":"Chen R, Zou J, Zhong X, Li J, Kang R, Tang D. Hmgb1 in the interplay between autophagy and apoptosis in cancer. Cancer Lett. 2024;581:216494. https:\/\/doi.org\/10.1016\/j.canlet.2023.216494.","journal-title":"Cancer Lett"},{"key":"1963_CR58","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s12276-024-01301-3","volume":"56","author":"SJ Im","year":"2024","unstructured":"Im SJ, Lee K, Ha S-J, Nature Publishing Group. Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends. Exp Mol Med. 2024;56:1900\u20138. https:\/\/doi.org\/10.1038\/s12276-024-01301-3.","journal-title":"Exp Mol Med"},{"key":"1963_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01664-8","volume":"18","author":"Z Li","year":"2025","unstructured":"Li Z, Wrangle J, He K, Sprent J, Rubinstein MP. IL-15: from discovery to FDA approval. J Hematol Oncol. 2025;18:19. https:\/\/doi.org\/10.1186\/s13045-025-01664-8.","journal-title":"J Hematol Oncol"},{"key":"1963_CR60","doi-asserted-by":"publisher","unstructured":"Feng B, Bai Z, Zhou X, Zhao Y, Xie Y-Q, Huang X, et al. The type 2 cytokine Fc\u2013IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature. 2024;634:712\u201320. https:\/\/doi.org\/10.1038\/s41586-024-07962-4.","DOI":"10.1038\/s41586-024-07962-4"},{"key":"1963_CR61","doi-asserted-by":"publisher","unstructured":"Pavicic Jr. PG, Rayman ,Patricia A., Swaidani ,Shadi, Rupani ,Amit, Makarov ,Vladimir, Tannenbaum ,Charles S., et al. Immunotherapy with IL12 and PD1\/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression. OncoImmunology. Taylor & Francis; 2023;12:2198185. https:\/\/doi.org\/10.1080\/2162402X.2023.2198185","DOI":"10.1080\/2162402X.2023.2198185"},{"key":"1963_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03077-7","volume":"24","author":"AA Hippen","year":"2023","unstructured":"Hippen AA, Omran DK, Weber LM, Jung E, Drapkin R, Doherty JA, et al. Performance of computational algorithms to deconvolve heterogeneous bulk ovarian tumor tissue depends on experimental factors. Genome Biol. 2023;24:239. https:\/\/doi.org\/10.1186\/s13059-023-03077-7.","journal-title":"Genome Biol"},{"key":"1963_CR63","doi-asserted-by":"publisher","unstructured":"Regner MJ, Wisniewska K, Garcia-Recio S, Thennavan A, Mendez-Giraldez R, Malladi VS, et al. A multi-omic single-cell landscape of human gynecologic malignancies. Mol Cell. 2021(23). https:\/\/doi.org\/10.1016\/j.molcel.2021.10.013.","DOI":"10.1016\/j.molcel.2021.10.013"},{"key":"1963_CR64","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1158\/0008-5472.CAN-20-0521","volume":"80","author":"L Geistlinger","year":"2020","unstructured":"Geistlinger L, Oh S, Ramos M, Schiffer L, LaRue RS, Henzler CM, et al. Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma. Cancer Res. 2020;80:4335\u201345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0521.","journal-title":"Cancer Res"},{"key":"1963_CR65","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","volume":"28","author":"J Xu","year":"2022","unstructured":"Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y, et al. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. Clin Cancer Res. 2022;28:3590\u2013602. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0296.","journal-title":"Clin Cancer Res"},{"key":"1963_CR66","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I V\u00e1zquez-Garc\u00eda","year":"2022","unstructured":"V\u00e1zquez-Garc\u00eda I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature. 2022;612:778\u201386. https:\/\/doi.org\/10.1038\/s41586-022-05496-1.","journal-title":"Nature"},{"key":"1963_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04094-7","volume":"21","author":"J Guo","year":"2023","unstructured":"Guo J, Han X, Li J, Li Z, Yi J, Gao Y, et al. Single-cell transcriptomics in ovarian cancer identify a metastasis-associated cell cluster overexpressed RAB13. J Transl Med. 2023;21:254. https:\/\/doi.org\/10.1186\/s12967-023-04094-7.","journal-title":"J Transl Med"},{"key":"1963_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1338","volume":"13","author":"Z Shi","year":"2023","unstructured":"Shi Z, Sun Z, Zhu Z, Liu X, Chen J, Hao L, et al. Integrated single-cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial\u2013fibroblast interactions in recurrent bladder cancer. Clin Transl Med. 2023;13:e1338. https:\/\/doi.org\/10.1002\/ctm2.1338.","journal-title":"Clin Transl Med"},{"key":"1963_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02074-6","volume":"10","author":"KH Prazanowska","year":"2023","unstructured":"Prazanowska KH, Lim SB. An integrated single-cell transcriptomic dataset for non-small cell lung cancer. Sci Data. 2023;10:167. https:\/\/doi.org\/10.1038\/s41597-023-02074-6.","journal-title":"Sci Data"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01963-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:10:56Z","timestamp":1783764656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01963-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01963-5","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors consent to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}